Hatteras’ mission is to create transformative healthcare companies in the research-driven, undercapitalized regions of the Southeast and Mid-Atlantic. Over half of our portfolio companies were created with our initial investment.

At Hatteras Venture Partners, we believe that breakthrough science and entrepreneurial innovation have the power to create valuable new ways of treating and diagnosing disease, providing value for our investors and transforming human health.

The Hatteras team brings operational experience, a renowned strategic partner network, and a successful investment track record. We are passionate about utilizing our backgrounds to engage entrepreneurs and enhance the value of their companies.


Latest News

Viamet Reports Positive Results from REVIVE Phase 2b Trial of Oral VT-1161 in Recurrent Vulvovaginal Candidiasis

January 18, 2017

-48 Week Results Demonstrate Strong Clinical Benefit and Very Favorable Safety Profile- RESEARCH TRIANGLE PARK, N.C., January 6, 2017, – Viamet Pharmaceuticals, Inc. today reported positive efficacy and safety results…

More News